NCT06106360 A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
| NCT ID | NCT06106360 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Inova Health Care Services |
| Condition | Solid Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-10-26 |
| Primary Completion | 2025-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-10-26 with a primary completion date of 2025-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.
Eligibility Criteria
Inclusion Criteria: * Planned to be treated with a new cytotoxic chemotherapy or chemoimmunotherapy regimen for a solid tumor or malignant hematology condition for at least 4 months * ECOG performance status of 0-2 * Age of 18 or older patient with any solid tumor or hematologic malignancy * English or Spanish speaker * Own an Apple iPhone * Capacity and willingness to provide informed consent Exclusion Criteria: * Patients undergoing concurrent radiation since they will be seen on a daily basis by clinic care teams and are not likely to benefit from active remote patient monitoring * Patients unwilling or unable to comply with the protocol, including wearing the Apple Watch (including recharging daily) and answering queries on the Locus Health iPhone application per the protocol and study group cadence * Any condition for which in the Investigator's opinion would limit compliance with study requirements
Contact & Investigator
John Deeken, MD
PRINCIPAL INVESTIGATOR
Inova Schar Cancer Institute
Frequently Asked Questions
Who can join the NCT06106360 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06106360 currently recruiting?
Yes, NCT06106360 is actively recruiting participants. Contact the research team at elahe.mollapour@inova.org for enrollment information.
Where is the NCT06106360 trial being conducted?
This trial is being conducted at Fairfax, United States.
Who is sponsoring the NCT06106360 clinical trial?
NCT06106360 is sponsored by Inova Health Care Services. The principal investigator is John Deeken, MD at Inova Schar Cancer Institute. The trial plans to enroll 100 participants.